Diagnostic Imaging Disease Radiation Radiopharmaceuticals 
AuntMinnie
MARCH 15, 2024
However, increased longevity has brought on a troubling rise in chronic disease, diminishing the quality of life later in life. Centers for Disease Control and Prevention (CDC) found that more than a quarter of U.S. An emerging field of precision radiopharmaceuticals brings new optimism to this mission, revolutionizing cancer care.
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Future Teleradiology
NOVEMBER 27, 2023
Discuss how theranostic approaches integrate diagnostic imaging and targeted therapy for more personalized and effective treatments. Discuss how this approach delivers radiation with exceptional precision to cancer cells. Discuss how these compounds are expanding therapeutic options for various diseases, including cancer.
AuntMinnie
JUNE 20, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.
Imaging Technology
MAY 30, 2023
milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. POSLUMA was developed to assist physicians in the detection and localization of prostate cancer.
Imaging Technology
JULY 28, 2023
POSLUMA represents a new class of high-affinity PSMA-targeted PET radiopharmaceuticals based on novel radiohybrid technology and is labeled with the radioisotope 18F to provide readily available patient access and leverage the high image quality of 18F-labeled PSMA PET imaging to facilitate effective detection of disease.
Imaging Technology
OCTOBER 5, 2023
Effective initial staging of prostate cancer, particularly with regards to the detection of metastatic disease, is critical to optimal clinical management of patients,” said Phillip H. Kuo, MD, Ph.D. , Departments of Medical Imaging, Medicine, and Biomedical Engineering.
Expert insights. Personalized for you.
105 
Let's personalize your content